hepatic impairment is a contraindication to many different medications. Of note in diabetes, is the use of glitazones in the case of hepatic impairment associated with non-alcoholic fatty liver disease
the first glitazone, thioglitazone, was withdrawn from use after deaths occurred secondary to hepatic failure. However now there is evidence that glitazones are an effective treatment in non-alcoholic fatty liver disease
the use of glitazone therapy in patients with abnormal liver function tests should only be used on specialist advice (1)
Reference:
Personal Communication (February 9th 2006). Aresh Anwar, Consultant Diabetologist, University Hospitals Coventry and Warwickshire.
Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.